Zentalis Pharmaceuticals (ZNTL) Stock: Buy, Sell, or Hold?
ZNTL - Zentalis Pharmaceuticals, Inc. Common Stock
$2.52
-0.08 (-3.26%)
▼
5d:
-6.67%
30d:
-33.16%
90d:
-46.61%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When ZNTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ZNTL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ZNTL shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ZNTL is currently trading at $2.52, which is considered oversold relative to its 30-day fair value range of $2.84 to $3.85.
Technical Outlook: Technically, ZNTL is in a uptrend. The price is currently testing key support at $2.50. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.89 (+173.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZNTL is in a uptrend. The price is currently testing key support at $2.50. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.89 (+173.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.84 -
$3.85
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 173.4% below Wall St target ($6.89)
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.84 -
$3.85
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.50
Resistance Level
$3.15
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.36
Wall Street Target
$6.89
(+173.4%)
Share & Embed Analysis
Last updated: October 03, 2026 2:23 PM ET
Data refreshes hourly during market hours. Next update: 3:23 PM
Data refreshes hourly during market hours. Next update: 3:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZNTL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 63 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
